Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

8.26
-0.1700-2.02%
Post-market: 8.260.00000.00%19:40 EDT
Volume:2.70M
Turnover:22.36M
Market Cap:729.60M
PE:-2.60
High:8.60
Open:8.43
Low:8.17
Close:8.43
52wk High:12.49
52wk Low:5.41
Shares:88.33M
Float Shares:63.99M
Volume Ratio:2.80
T/O Rate:4.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1784
EPS(LYR):-3.1784
ROE:-94.82%
ROA:-25.33%
PB:4.19
PE(LYR):-2.60

Loading ...

Kura Oncology Unveils Precision Medicine Advances and Pipeline Expansion in New Corporate Presentation

Reuters
·
Jan 13

Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA)

TIPRANKS
·
Jan 12

Kura Oncology projects $45M–$55M in non-cash collaboration revenue for 2026

Reuters
·
Jan 12

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

GlobeNewswire
·
Jan 12

Kura Oncology Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Jan 05

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 05

Kura Oncology Chief Scientific Officer Francis Burrows Reports Disposal of Common Shares

Reuters
·
Dec 20, 2025

Kura Oncology Director Faheem Hasnain Reports Disposal of Common Shares

Reuters
·
Dec 11, 2025

Kura Oncology Inc - Registrational Trials of Ziftomenib in Front-Line Aml Ongoing

THOMSON REUTERS
·
Dec 08, 2025

Kura Oncology Inc - Triplet Combination for Komzifti With Venetoclax and Azacitidine Well Tolerated in Newly Diagnosed and R/R Settings

THOMSON REUTERS
·
Dec 08, 2025

Kura Oncology Reports Positive Data for KOMZIFTI Triplet Combo in AML Trial

Reuters
·
Dec 08, 2025

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

GlobeNewswire
·
Dec 08, 2025

Kura Oncology Hosts Virtual Investor Event on Ziftomenib Triplet Data in Acute Myeloid Leukemia

Reuters
·
Dec 03, 2025

Kura Oncology Secures $135 Million Milestone Payment from Kyowa Kirin

Reuters
·
Dec 02, 2025

First U.S. Commercial Sale of Komzifti™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement With Kyowa Kirin

THOMSON REUTERS
·
Dec 02, 2025

Positive Outlook on Kura Oncology: Komzii’s Approval and Safety Profile Drive Buy Rating

TIPRANKS
·
Nov 26, 2025

FDA Approves Kura Oncology’s KOMZIFTI for Relapsed or Refractory NPM1-Mutated AML

Reuters
·
Nov 26, 2025

Kura Oncology Is Maintained at Overweight by Barclays

Dow Jones
·
Nov 24, 2025

Barclays Remains a Buy on Kura Oncology (KURA)

TIPRANKS
·
Nov 24, 2025

Kura Oncology Receives Second $30 Million Development Milestone Payment In Aml Menin Inhibitor Program With Kyowa Kirin

Reuters
·
Nov 20, 2025